Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition

Protein Science

Volumn 20, Issue 2, 2011, Pages 353-365

  Thompson, Lawrence C ^a   Goswami, Sumit ^a   Ginsberg, David S ^b   Day, Duane E ^b   Verhamme, Ingrid M ^c   Peterson, Cynthia B ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b Molecular Innovations Inc   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Metal; PAI 1; Serpin; Vitronectin

Indexed keywords

CALCIUM; COBALT; COPPER; MAGNESIUM; MANGANESE; METAL DERIVATIVE; NICKEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR; VITRONECTIN;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME STABILITY; HUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN STRUCTURE;

BINDING SITES; CALCIUM; CHLORIDES; CHROMATOGRAPHY, AFFINITY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; KINETICS; MAGNESIUM; METALS, HEAVY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN STABILITY; SOMATOMEDINS; VITRONECTIN;

EID: 79251534038     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.568     Document Type: Article

References (75)

1. Melchor JP, Strickland S (2005) Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 93:655-660.
2. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M, Romer J (2005) Plasminogen activation and cancer. Thromb Haemost 93:676-681.
3. Collen D, Lijnen HR (2005) Thrombolytic agents. Thromb Haemost 93:627-630.
4. Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, Lund LR (1999) Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. Apmis 107:120-127.
5. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, Devos R, Vandenoord JJ, Collen D, Mulligan RC (1994) Physiological consequences of loss of plasminogen-activator gene-function in mice. Nature 368:419-424.
6. Dano K, Andreasen PA, Grondahlhansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266.
7. Huntington JA, Carrell RW (2001) The serpins: nature's molecular mousetraps. Sci Prog 84:125-136.
8. Huntington JA, Read RJ, Carrell RW (2000) Structure of a serpin-protease complex shows inhibition by deformation. Nature 407:923-926.
9. Olson ST, Swanson R, Day D, Verhamme I, Kvassman J, Shore JD (2001) Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin. Biochemistry 40:11742-11756.
10. Lawrence DA, Ginsburg D, Day DE, Berkenpas MB, Verhamme IM, Kvassman JO, Shore JD (1995) Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 270:25309-25312.
11. Stout TJ, Graham H, Buckley DI, Matthews DJ (2000) Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry 39: 8460-8469. (Pubitemid 30489942)
12. Mathiasen L, Dupont DM, Christensen A, Blouse GE, Jensen JK, Gils A, Declerck PJ, Wind T, Andreasen PA (2008) A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. Mol Pharmacol 74:641-653.
13. Li SH, Gorlatova NV, Lawrence DA, Schwartz BS (2008) Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands. J Biol Chem 283: 18147-18157.
14. Wind T, Jensen JK, Dupont DM, Kulig P, Andreasen PA (2003) Mutational analysis of plasminogen activator inhibitor-1. Eur J Biochem 270:1680-1688.
15. Gils A, Pedersen KE, Skottrup P, Christensen A, Naessens D, Deinum J, Enghild JJ, Declerck PJ, Andreasen PA (2003) Biochemical importance of glycosylation of plasminogen activator inhibitor-1. Thromb Haemost 90: 206-217.
16. Blouse GE, Perron MJ, Kvassman JO, Yunus S, Thompson JH, Betts RL, Lutter LC, Shore JD (2003) Mutation of the highly conserved tryptophan in the serpin breach region alters the inhibitory mechanism of plasminogen activator inhibitor-1. Biochemistry 42: 12260-12272.
17. Hansen M, Busse MN, Andreasen PA (2001) Importance of the amino-acid composition of the shutter region of plasminogen activator inhibitor-1 for its transitions to latent and substrate forms. Eur J Biochem 268:6274-6283.
18. Vleugels N, Leys J, Knockaert I, Declerck PJ (2000) Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1. Thromb Haemost 84: 871-875.
19. Mangs H, Sui GC, Wiman B (2000) PAI-1 stability: the role of histidine residues. FEBS Lett 475:192-196.
20. Berkenpas MB, Lawrence DA, Ginsburg D (1995) Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J 14:2969-2977.
21. Lindahl TL, Sigurdardottir O, Wiman B (1989) Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 62:748-751.
22. Deng G, Curriden SA, Hu G, Czekay RP, Loskutoff DJ (2001) Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J Cell Physiol 189:23-33.
23. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563-1571.
24. Deng G, Royle G, Wang S, Crain K, Loskutoff DJ (1996) Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem 271: 12716-12723. (Pubitemid 126545201)
25. Kamikubo Y, De Guzman R, Kroon G, Curriden S, Neels JG, Churchill MJ, Dawson P, Oldziej S, Jagielska A, Scheraga HA, Loskutoff DJ, Dyson HJ (2004) Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin. Biochemistry 43: 6519-6534.
26. Lawrence DA, Palaniappan S, Stefansson S, Olson ST, Francis-Chmura AM, Shore JD, Ginsburg D (1997) Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin. Implications for the regulation of pericellular proteolysis. J Biol Chem 272:7676-7680.
27. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ (2003) How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10: 541-544.
28. Declerck PJ, De Mol M, Alessi MC, Baudner S, Paques EP, Preissner KT, Muller-Berghaus G, Collen D (1988) Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 263:15454-15461.
29. Molecular Innovations, Inc. Method for making purified plasminogen activator inhibitor Type-1 (PAI-1) and purified PAI-1 made therefrom. U.S. Pat. 7,015,021 B2, March 21, 2006.
30. Sharp AM, Stein PE, Pannu NS, Carrell RW, Berkenpas MB, Ginsburg D, Lawrence DA, Read RJ (1999) The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 7:111-118.
31. Nan R, Gor J, Lengyel I, Perkins SJ (2008) Uncontrolled zinc- and copper-induced oligomerisation of the human complement regulator factor H and its possible implications for function and disease. J Mol Biol 384:1341-1352.
32. Herrera JE, Correia JJ, Jones AE, Olson MO (1996) Sedimentation analyses of the salt- and divalent metal ion-induced oligomerization of nucleolar protein B23. Biochemistry 35:2668-2673.
33. Paik SR, Shin HJ, Lee JH, Chang CS, Kim J (1999) Copper(II)-induced self-oligomerization of alpha-synuclein. Biochem J 340:821-828.
34. Salgado EN, Lewis RA, Faraone-Mennella J, Tezcan FA (2008) Metal-mediated self-assembly of protein superstructures: influence of secondary interactions on protein oligomerization and aggregation. J Am Chem Soc 130:6082-6084.
35. Blouse GE, Dupont DM, Schar CR, Jensen JK, Minor KH, Anagli JY, Gardsvoll H, Ploug M, Peterson CB, Andreasen PA (2009) Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements. Biochemistry 48:1723-1735.
36. Schar CR, Jensen JK, Christensen A, Blouse GE, Andreasen PA, Peterson CB (2008) Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem 283:28487-28496.
37. Schar CR, Blouse GE, Minor KH, Peterson CB (2008) A deletion mutant of vitronectin lacking the somatomedin B domain exhibits residual PAI-1-binding activity. J Biol Chem 283:10297-10309.
38. Lawrence LC, Goswami S, Peterson CB. (2011) Metals affect the structure and activity of human plasminogen activator inhibitor-1. II Binding affinity and conformational changes. Prot Sci 2:366-378.
39. Nieboer E, Richardson DHS.(1980) The replacement of the non-descript term heavy-metals by a biologically and chemically significant classification of metal-ions. Environ Poll B Chem Phys 1:3-26.
40. Bock CW, Katz AK, Markham GD, Glusker JP (1999) Manganese as a replacement for magnesium and zinc: functional comparison of the divalent ions. J Am Chem Soc 121:7360-7372.
41. Fricker SP (1996) Medical uses of gold compounds: past, present, and future. Gold Bull 29:53-60.
42. Parish RV, Cottrill SM (1987) Medicinal gold compounds. Gold Bull 20:3-12.
43. Turski ML, Thiele DJ (2009) New roles for copper metabolism in cell proliferation, signaling, and disease. J Biol Chem 284:717-721.
44. Williams RJ (1997) The natural selection of the chemical elements. Cell Mol Life Sci 53:816-829.
45. Jensen JK, Gettins PGW (2008) High-resolution structure of the stable plasminogen activator inhibitor type- 1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling. Protein Sci 17:1844-1849.
46. Xue YF, Bjorquist P, Inghardt T, Linschoten M, Musil D, Sjolin L, Deinum J (1998) Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Struct Fold Des 6:627-636.
47. Tucker HM, Mottonen J, Goldsmith EJ, Gerard RD (1995) Engineering of plasminogen-activator inhibitor-1 to reduce the rate of latency transition. Nat Struct Biol 2:442-445.
48. Aertgeerts K, Debondt HL, Deranter CJ, Declerck PJ (1995) Mechanisms contributing to the conformational and functional flexibility of plasminogen-activator inhibitor- 1. Nat Struct Biol 2:891-897.
49. Gils A, Declerck PJ (1998) Structure-function relationships in serpins: current concepts and controversies. Thromb Haemost 80:531-541.
50. Dementiev A, Dobo J, Gettins PGW (2006) Active site distortion is sufficient for proteinase inhibition by serpins- structure of the covalent complex of alpha(1)-proteinase inhibitor with porcine pancreatic elastase. J Biol Chem 281:3452-3457.
51. Huntington JA, Read RJ, Carrell RW (2000) Structure of a serpin-protease complex shows inhibition by deformation. Nature 407:923-926.
52. Johnson DJ, Langdown J, Li W, Luis SA, Baglin TP, Huntington JA (2006) Crystal structure of monomeric native antithrombin reveals a novel reactive center loop conformation. J Biol Chem 281:35478-35486.
53. Zhang Q, Law RH, Bottomley SP, Whisstock JC, Buckle AM (2008) A structural basis for loop C-sheet polymerization in serpins. J Mol Biol 376:1348-1359.
54. Na YR, Im H (2005) The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor-1. Protein Sci 14:55-63.
55. Al-Ayyoubi M, Gettins PG, Volz K (2004) Crystal structure of human maspin, a serpin with antitumor properties: reactive center loop of maspin is exposed but constrained. J Biol Chem 279:55540-55544.
56. Hagglof P, Bergstrom F, Wilczynska M, Johansson LB, Ny T (2004) The reactive-center loop of active PAI-1 is folded close to the protein core and can be partially inserted. J Mol Biol 335:823-832.
57. Yamasaki M, Takahashi N, Hirose M (2003) Crystal structure of S-ovalbumin as a non-loop-inserted thermostabilized serpin form. J Biol Chem 278: 35524-35530. (Pubitemid 37102324)
58. Sivasothy P, Dafforn TR, Gettins PG, Lomas DA (2000) Pathogenic alpha 1-antitrypsin polymers are formed by reactive loop-beta-sheet A linkage. J Biol Chem 275: 33663-33668.
59. Podor TJ, Peterson CB, Lawrence DA, Stefansson S, Shaughnessy SG, Foulon DM, Butcher M, Weitz JI (2000) Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin. J Biol Chem 275:19788-19794.
60. Owensby DA, Morton PA, Wun TC, Schwartz AL (1991) Binding of plasminogen activator inhibitor type- 1 to extracellular matrix of Hep G2 cells. Evidence that the binding protein is vitronectin. J Biol Chem 266: 4334-4340.
61. Hedberg KK, Stauff C, Hoyer-Hansen G, Ronne E, Griffith OH (2000) High-molecular-weight serum protein complexes differentially promote cell migration and the focal adhesion localization of the urokinase receptor in human glioma cells. Exp Cell Res 257:67-81.
62. Nakamura T, Tanaka N, Higuma N, Kazama T, Kobayashi I, Yokota S (1996) The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy. J Am Soc Nephrol 7:2434-2444.
63. Inuzuka S, Ueno T, Torimura T, Tamaki S, Sugawara H, Sakata R, Kusaba N, Sata M, Tanikawa K (1997) The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis. Scand J Gastroenterol 32:1052-1060.
64. Stoop AA, Lupu F, Pannekoek H (2000) Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: a potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes. Arterioscler Thromb Vasc Biol 20:1143-1149.
65. Preissner KT (1990) Specific binding of plasminogen to vitronectin. Evidence for a modulatory role of vitronectin on fibrin(ogen)-induced plasmin formation by tissue plasminogen activator. Biochem Biophys Res Commun 168:966-971.
66. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA (2001) Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 276:8135-8141.
67. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, Ginsburg D, Brooks PC, Lawrence DA (2001) Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276:33964-33968.
68. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, Carmeliet G, Loskutoff D, Collen D, Carmeliet P, Foidart JM, Noel A (2001) The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 152:777-784.
69. Vaughan DE, Declerck PJ, Reilly TM, Park K, Collen D, Fasman GD (1993) Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1). Biochim Biophys Acta 1202: 221-229.
70. Bittorf SV, Williams EC, Mosher DF (1993) Alteration of vitronectin. Characterization of changes induced by treatment with urea. J Biol Chem 268:24838-24846.
71. Dahlback B, Podack ER (1985) Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group. Biochemistry 24:2368-2374.
72. Preissner KT, Heimburger N, Anders E, Muller-Berghaus G (1986) Physicochemical, immunochemical and functional comparison of human S-protein and vitronectin. Evidence for the identity of both plasma proteins. Biochem Biophys Res Commun 134:951-956.
73. Zhuang P, Blackburn MN, Peterson CB (1996) Characterization of the denaturation and renaturation of human plasma vitronectin. I. Biophysical characterization of protein unfolding and multimerization. J Biol Chem 271:14323-14332.
74. Lynn GW, Heller WT, Mayasundari A, Minor KH, Peterson CB (2005) A model for the three-dimensional structure of human plasma vitronectin from smallangle scattering measurements. Biochemistry 44: 565-574.
75. Edelhoch H (1967) Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry 6: 1948-1954.